Witness Testimony

Dr. Sabine Hazan, a gastroenterologist and microbiome researcher, testified regarding her clinical and laboratory work during the COVID-19 period. Drawing on her experience conducting pharmaceutical clinical trials and operating a genetic sequencing laboratory, she described investigating SARS-CoV-2 in stool samples and reported detecting viral genetic material in patients with positive nasal PCR tests. She outlined treatment protocols she used in FDA-approved trials and off-label settings, including hydroxychloroquine, azithromycin, zinc, ivermectin, vitamin C, and vitamin D, and stated that she observed improvements in oxygen saturation among certain patients treated with ivermectin. She reported treating several hundred patients within clinical protocols and additional patients outside formal trials.
Central to her testimony was the hypothesis that gut microbiome composition—particularly levels of bifidobacteria—plays a critical role in resilience to COVID-19. She described comparative analyses of families in which some members developed severe disease while others remained asymptomatic, reporting that individuals with higher bifidobacteria levels appeared less affected. She further stated that post-vaccination microbiome testing in certain patients showed significant declines in bifidobacteria, which she hypothesized may contribute to vulnerability to infection or other health issues. She also described exploratory protocols for long COVID and vaccine-related conditions involving microbiome modulation.
Dr. Hazan expressed frustration with what she characterized as research interference, publication barriers, and social media content removal, stating that political and media narratives discouraged alternative scientific hypotheses. She argued that microbiome research remains in its infancy and requires greater institutional support. In her concluding remarks, she criticized aspects of vaccine research design, including limited animal studies and absence of microbiome analysis, and emphasized the importance of individualized resilience, nutritional support, and further investigation into gut-immune interactions.